EUVIMEDEUVIMED entdecken
Crossref

Treatment Outcome of Children with Acute Lymphoblastic Leukemia According to Risk-Group Stratification: A Single Institution Experience

Juyeon Lee, Young Bae Choi, Hyun Joo Jung, Jun Eun Park

Cancer Research and Treatment · 15.07.2026

DOI: 10.4143/crt.2026.0421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 15.07.2026. Verfasst von Juyeon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Outcomes of children and adolescents with acute lymphoblastic leukemia (ALL) treated using an institutional risk-adapted strategy were assessed, and survival was compared among risk groups. Materials and Methods: This retrospective study included patients newly diagnosed with ALL during 2006-2020. Patients were stratified as standard-risk (SR), high-risk (HR), or very-high-risk (VHR). The SR group received a POG 9605-based protocol in 2006-2011 and a modified regimen with an additional delayed intensification phase in 2012-2020. The HR group received the ALL 0601 regimen, and the VHR group received institutional hematopoietic stem cell transplantation-oriented treatment.

Results

Ninety-two patients were included (SR, 34; HR, 45; and VHR, 13). The 10-year overall survival (OS) and event-free survival (EFS) were 85.2% and 70.9%, with cumulative incidences of relapse and treatment-related mortality of 22.6% and 3.3%, respectively. The 10-year OS was 92.8%, 88.7%, and 60.9% in the SR, HR, and VHR groups, and the corresponding 10-year EFS was 78.5%, 77.2%, and 34.2%, respectively. In SR, 10-year OS/EFS were 85.1%/71.4% in 2006-2011 and 100%/84.4% in 2012-2020. In the HR group, rapid early responders exhibited significantly better outcomes than did slow early responders, with 10-year OS of 97.0% vs. 63.6% (p = 0.001) and 10-year EFS of 87.9% vs. 43.6% (p < 0.001). Most relapses occurred during therapy or within 3 years of treatment completion.

Conclusion

VHR patients and HR patients with slow early response demonstrated the poorest outcomes. This supports refining risk-directed treatment strategies, including prospective evaluation of intensified and novel therapeutic approaches.

Schlagwörter

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaPediatricsPrognosisRisk factors

Autor:innen und Institutionen

  • Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.
  • Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea. zero-ship@hanmail.net.
  • Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Zitieren

APA

Lee, J., Choi, Y. B., Jung, H. J., & Park, J. E. (2026). Treatment Outcome of Children with Acute Lymphoblastic Leukemia According to Risk-Group Stratification: A Single Institution Experience. Cancer Research and Treatment. https://doi.org/10.4143/crt.2026.0421

Vancouver

Lee J, Choi YB, Jung HJ, Park JE. Treatment Outcome of Children with Acute Lymphoblastic Leukemia According to Risk-Group Stratification: A Single Institution Experience. Cancer Research and Treatment. 2026. doi:10.4143/crt.2026.0421

BibTeX
@article{Lee2026,
  author = {Lee, Juyeon and Choi, Young Bae and Jung, Hyun Joo and Park, Jun Eun},
  title = {Treatment Outcome of Children with Acute Lymphoblastic Leukemia According to Risk-Group Stratification: A Single Institution Experience},
  journal = {Cancer Research and Treatment},
  year = {2026},
  doi = {10.4143/crt.2026.0421}
}
Kostenlos starten →